The Board of Directors of Concord Biotech Limited, in their meeting held on May 29, 2026, approved the audited standalone and consolidated financial results for the fourth quarter and the financial year ended March 31, 2026. The company also declared a final dividend of Rs. 7.55 per equity share of face value Re. 1 each for the financial year 2025-26, subject to shareholder approval. Furthermore, the Board approved the appointment of M/s. Manubhai & Shah LLP as Internal Auditor and M/s. Dalwadi & Associates as Cost Auditor for the financial year 2026-27, alongside the appointment of Mrs. Ekta Gupta as an Additional Independent Director.

Concord Biotech Limited is a prominent biotechnology company based in Ahmedabad, Gujarat, specializing in the manufacturing and trading of pharmaceutical products. Operating as a significant player in the biopharmaceutical sector, the company focuses on complex fermentation-based APIs and finished formulations. In 2025, the company continued its trajectory of business expansion, including the strategic acquisition of subsidiaries to bolster its global footprint and manufacturing capabilities. The company is known for its extensive R&D-driven approach, which allows it to maintain a competitive edge in the global market.

Concord Biotech Limited reported a robust performance in the fourth quarter ending March 31, 2026. Standalone revenue from operations stood at 32,589.20 Lakhs, representing a 17.17% increase quarter-on-quarter (QoQ) compared to 27,813.39 Lakhs in the previous quarter, though it experienced a 24.19% decrease year-on-year (YoY) compared to 42,988.38 Lakhs in the same quarter last year. Profit after tax for the current quarter was 9,002.21 Lakhs, a 32.81% increase QoQ, but a 36.58% decrease YoY. The company’s financial performance highlights its resilience in managing operational costs and market fluctuations during the fiscal year.